biomedicina slovenica

pr=Bonnefoi : 11

  1. Bonnefoi Herve; Jacot W.; Saghatchian M.; Moldovan C.; Venat-Bouvet L.; Zaman Khurshid; Matos Erika; Petit T.; Bodmer A.; Quenel-Tueux N.; Chakiba C.
    Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer
    2015 ►
  2. Bonnefoi Herve; Čufer Tanja
    Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes
    2014 ►
  3. Bonnefoi Herve; Piccart Martine; Bogaerts Jan; Čufer Tanja
    TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial
    2011 ►
  4. Maillet P; Bonnefoi H; Vaudan-Vutskits G; Pajk B; Čufer T; Foulkes WD; Chappuis PO; Sappino AP
    Constitutional alterations of the ATM gene in early onset sporadic breast cancer
    2002 ►
  5. Therasse P; Mauriac L; Welnicka-Jaskiewicz M; Bruning P; Čufer T; Bonnefoi H; Tomiak E; Pritchard KI; Hamilton A; Piccart MJ
    Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study
    2003 ►
  6. Bonnefoi H; Biganzoli L; Mauriac L; Čufer T; Schaefer P; Atalay G; Piccart M
    An EORTC phase I study of capecitabine (xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer
    2003 ►
  7. Biganzoli L; Bonnefoi H; Mauriac L; Čufer T; Kabanga-Ngalula E; Hebert D; Piccart M
    Cyclophosphamide (C) - Epirubicine (E) - Capecitabine (X) combination, CEX: a safe and active regimen in the treatment of locally advanced/inflammatory (LA/I) or large operable (LO) breast cancer (BC). An EORTC-IDBBC study
    2001 ►
  8. Bonnefoi H; Biganzoli L; Čufer T; Mauriac L; Hamilton A; Schaefer P; Picart M
    An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer
    2001 ►
  9. Bonnefoi H; Biganzoli L; Mauriac L; Čufer T; Yague C; Hebert D; Piccart M
    An EORTC-IDBBC phase I study of cyclophosphamide (C) and epirubicin (E) in combination with capecitabine (X) (CEX) as primary treatment of locally advanced / inflammatory (LA/I) or large operable (LO) breast cancer (BC)
    2001 ►
  10. Bonnefoi H; Biganzoli L; Čufer T; Hamilton A; Mauriac L; Van Hoorebeeck I; Piccart M
    A feasibility study of epirubicin (E) in combination with cyclophosphamide (C) and infusional 5-fluorouracil (F-infu)(CEF-infu) as primary treatment of large operable (LO) or locally advanced/inflammatory (LA/I) breast cancer (BC)
    1999 ►
  11. Therasse P; Mauriac L; Welincka M; Bruning P; Čufer T; Bonnefoi H; Tomiak E; Hamilton A; Piccart M
    Neo-adjuvant dose intensive chemotherapy in locally advanced breast cancer (LABC): an EORTC-NCIC-SAKK randomized phase 3 study comparing FEC (5FU, epirubicin, cyclophosphamide) VS high dose intensity EC + G-CSF (filgrastim)
    1998 ►

New search      Comments      Top of page Institute for Biostatistics and Medical Informatics